RxDoctor Payments Data

Crystal Kolling, APRN

Nurse Practitioner · Tabor City, NCNPI 1073184396

Payments from drug & device makers

$1,498in general payments, 2019–2025

Across 74 payments — averaging $20.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$262
  • Novo Nordisk$206
  • Lilly USA, LLC$164
  • AstraZeneca$140
  • Astellas Pharma US Inc$135
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$64
  • plus $526 from 18 others

What the payments were for

  • Food & beverage$1,39893%
  • Education$1007%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,498 in reported general payments places this provider in the 80th percentile of 4,393 nurse practitioner providers in North Carolina.

See all nurse practitioner providers in North Carolina

Medicare billing

Part B allowed, 2024
$115,412
Medicare patients
183
Services billed
2,214

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide134$151,192
EliquisApixaban114$97,076
FarxigaDapagliflozin Propanediol106$75,950
JardianceEmpagliflozin52$47,890
LinzessLinaclotide47$36,574
MounjaroTirzepatide33$36,485
JanuviaSitagliptin Phosphate43$30,332
Trelegy ElliptaFluticasone/Umeclidin/Vilanter39$26,606
Omnipod Dash Pods (Gen 4)Insulin Pump Cart,cont Inf,bt11$18,188
EntrestoSacubitril/Valsartan18$14,611
Breztri AerosphereBudesonide/Glycopyr/Formoterol19$12,213
XareltoRivaroxaban12$11,682
InvokanaCanagliflozin14$10,249
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog14$9,875
Tresiba Flextouch U-200Insulin Degludec20$6,949

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$206$151,192134 claims
AstraZenecaFarxiga, Breztri Aerosphere$140$88,163125 claims
Lilly USA, LLCMounjaro, Humalog$164$43,08452 claims
AbbVieLinzess$262$36,57447 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,393 nurse practitioner providers in North Carolina.

Other nurse practitioner in Tabor City

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →